Compare MTEX & NCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MTEX | NCEL |
|---|---|---|
| Founded | 1993 | 2008 |
| Country | United States | Switzerland |
| Employees | N/A | 11 |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.0M | 13.2M |
| IPO Year | 1998 | N/A |
| Metric | MTEX | NCEL |
|---|---|---|
| Price | $6.95 | $2.45 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 2.3K | ★ 16.4K |
| Earning Date | 05-12-2026 | 04-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 210.00 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $117,866,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.14 | $1.89 |
| 52 Week High | $12.45 | $4.70 |
| Indicator | MTEX | NCEL |
|---|---|---|
| Relative Strength Index (RSI) | 42.43 | 38.18 |
| Support Level | $6.14 | $1.89 |
| Resistance Level | $7.68 | $3.16 |
| Average True Range (ATR) | 0.22 | 0.16 |
| MACD | 0.05 | -0.03 |
| Stochastic Oscillator | 36.47 | 10.81 |
Mannatech Inc is a wellness solution provider. The company develops and sells nutritional supplements, topical and skin care and anti-aging products, and weight-management products that target optimal health and wellness. Mannatech sells products in three regions: the Americas (the United States, Canada, and Mexico); Europe/the Middle East/Africa (EMEA) (Austria, the Czech Republic, Denmark, Estonia, Finland, Germany, the Republic of Ireland, Namibia, the Netherlands, Norway, South Africa, Spain, Sweden, and the United Kingdom); and Asia/Pacific (Australia, Japan, New Zealand, the Republic of Korea, Singapore, Taiwan, Hong Kong, and China). Mannatech generates the majority of its revenue from the Americas.
NewcelX Ltd is a biotechnology company developing transformative cell-based and small-molecule therapies for neurodegenerative and metabolic diseases. The company's integrated platform combines advanced stem-cell technologies and neuroscience expertise to deliver scalable, regenerative treatments targeting conditions such as Amyotrophic Lateral Sclerosis (ALS) and Type 1 Diabetes. It has research and development operations in Ness Ziona, Israel.